{"id":3683,"date":"2020-10-01T12:05:12","date_gmt":"2020-10-01T11:05:12","guid":{"rendered":"https:\/\/www.ab-science.com\/cancer-de-la-prostate\/"},"modified":"2022-08-23T12:55:58","modified_gmt":"2022-08-23T11:55:58","slug":"cancer-de-la-prostate","status":"publish","type":"page","link":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/cancer-de-la-prostate\/","title":{"rendered":"Cancer de la Prostate"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column]<div class=\"dt-fancy-separator title-left h3-size title-color accent-border-color\" style=\"width: 100%;\"><div class=\"dt-fancy-title\"><span class=\"separator-holder separator-left\"><\/span>\u00c0 propos du Cancer de la Prostate<span class=\"separator-holder separator-right\"><\/span><\/div><\/div><div class=\"ult-spacer spacer-69e19ad72a6d4\" data-id=\"69e19ad72a6d4\" data-height=\"20\" data-height-mobile=\"10\" data-height-tab=\"20\" data-height-tab-portrait=\"20\" data-height-mobile-landscape=\"10\" style=\"clear:both;display:block;\"><\/div>[vc_column_text]Le cancer de la prostate est l\u2019un des types de cancer les plus courants chez l\u2019homme. Il y a toujours le besoin d\u2019un nouveau traitement en premi\u00e8re ligne plus efficace dans le cancer de la prostate m\u00e9tastatique r\u00e9sistant \u00e0 la castration (mCPRC), car les th\u00e9rapies r\u00e9centes approuv\u00e9es pour le CPRC sont des m\u00e9dicaments utilis\u00e9s soit avant la chimioth\u00e9rapie, soit dans le cancer de la prostate non m\u00e9tastatique r\u00e9sistant \u00e0 la castration. Le seul m\u00e9dicament approuv\u00e9 pour le traitement du cancer de la prostate m\u00e9tastatique r\u00e9sistant \u00e0 la castration et \u00e9ligible \u00e0 la chimioth\u00e9rapie est le doc\u00e9taxel.[\/vc_column_text]<div class=\"dt-fancy-separator title-left h3-size title-color accent-border-color\" style=\"width: 100%;\"><div class=\"dt-fancy-title\"><span class=\"separator-holder separator-left\"><\/span>Le positionnement du masitinib dans le Cancer de la Prostate<span class=\"separator-holder separator-right\"><\/span><\/div><\/div><div class=\"ult-spacer spacer-69e19ad72a750\" data-id=\"69e19ad72a750\" data-height=\"20\" data-height-mobile=\"10\" data-height-tab=\"20\" data-height-tab-portrait=\"20\" data-height-mobile-landscape=\"10\" style=\"clear:both;display:block;\"><\/div>[vc_column_text]Le masitinib est actuellement d\u00e9velopp\u00e9 en premi\u00e8re ligne pour le CRPC. Cette population de patients est constitu\u00e9e de patients qui pr\u00e9sentent une progression de la maladie malgr\u00e9 une th\u00e9rapie de d\u00e9pl\u00e9tion des androg\u00e8nes (castration m\u00e9dicale).[\/vc_column_text]<div class=\"dt-fancy-separator title-left h3-size title-color accent-border-color\" style=\"width: 100%;\"><div class=\"dt-fancy-title\"><span class=\"separator-holder separator-left\"><\/span>Nombre de patients cibl\u00e9s par le masitinib dans le Cancer de la Prostate<span class=\"separator-holder separator-right\"><\/span><\/div><\/div><div class=\"ult-spacer spacer-69e19ad72a7b9\" data-id=\"69e19ad72a7b9\" data-height=\"20\" data-height-mobile=\"10\" data-height-tab=\"20\" data-height-tab-portrait=\"20\" data-height-mobile-landscape=\"10\" style=\"clear:both;display:block;\"><\/div>[vc_column_text]Le nombre de patients cibl\u00e9s par le masitinib s&rsquo;\u00e9l\u00e8ve \u00e0 125 000 en Europe et aux \u00c9tats-Unis.[\/vc_column_text]<div class=\"dt-fancy-separator title-left h3-size title-color accent-border-color\" style=\"width: 100%;\"><div class=\"dt-fancy-title\"><span class=\"separator-holder separator-left\"><\/span>R\u00e9sultats positifs de phase 1\/2 du masitinib dans le Cancer de la Prostate<span class=\"separator-holder separator-right\"><\/span><\/div><\/div><div class=\"ult-spacer spacer-69e19ad72a81c\" data-id=\"69e19ad72a81c\" data-height=\"20\" data-height-mobile=\"10\" data-height-tab=\"20\" data-height-tab-portrait=\"20\" data-height-mobile-landscape=\"10\" style=\"clear:both;display:block;\"><\/div>[vc_column_text]Cette \u00e9tude de phase 1\/2, ayant inclus des patients atteints d\u2019un cancer de la prostate hormono-r\u00e9sistant en progression apr\u00e8s une premi\u00e8re ligne de traitement, a test\u00e9 la combinaison du masitinib avec le doc\u00e9taxel. La survie globale m\u00e9diane a atteint 18,4 mois avec la combinaison masitinib plus docetaxel.. Cette survie m\u00e9diane se compare favorablement \u00e0 une m\u00e9ta-analyse de la survie globale de 14,4 mois (apr\u00e8s l\u2019arriv\u00e9e de l\u2019enzalutamide).[\/vc_column_text]<div class=\"dt-fancy-separator title-left h3-size title-color accent-border-color\" style=\"width: 100%;\"><div class=\"dt-fancy-title\"><span class=\"separator-holder separator-left\"><\/span>R\u00e9sultats positifs de phase 2\/3 du masitinib dans le Cancer de la Prostate<span class=\"separator-holder separator-right\"><\/span><\/div><\/div><div class=\"ult-spacer spacer-69e19ad72a8b0\" data-id=\"69e19ad72a8b0\" data-height=\"20\" data-height-mobile=\"10\" data-height-tab=\"20\" data-height-tab-portrait=\"20\" data-height-mobile-landscape=\"10\" style=\"clear:both;display:block;\"><\/div>[vc_column_text]L&rsquo;\u00e9tude de phase 2\/3 du masitinib dans le cancer de la prostate m\u00e9tastatique hormono-r\u00e9sistant (mCRPC) \u00e9ligible \u00e0 la chimioth\u00e9rapie a atteint son crit\u00e8re d&rsquo;\u00e9valuation principal pr\u00e9d\u00e9fini. Les r\u00e9sultats de l&rsquo;\u00e9tude ont \u00e9t\u00e9 pr\u00e9sent\u00e9s lors du congr\u00e8s annuel 2021 de l&rsquo;American Urological Association (AUA) qui s&rsquo;est tenu en septembre 2021.[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text]Le cancer de la prostate est l\u2019un des types de cancer les plus courants chez l\u2019homme. Il y a toujours le besoin d\u2019un nouveau traitement en premi\u00e8re ligne plus efficace dans le cancer de la prostate m\u00e9tastatique r\u00e9sistant \u00e0 la castration (mCPRC), car les th\u00e9rapies r\u00e9centes approuv\u00e9es pour le CPRC sont des m\u00e9dicaments utilis\u00e9s soit&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":3763,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3683","page","type-page","status-publish","hentry","description-off"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.4 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cancer de la Prostate &#8211; AB Science<\/title>\n<meta name=\"description\" content=\"Le masitinib est actuellement d\u00e9velopp\u00e9 en premi\u00e8re ligne pour le cancer de la prostate m\u00e9tastatique r\u00e9sistant \u00e0 la castration.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/cancer-de-la-prostate\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cancer de la Prostate\" \/>\n<meta property=\"og:description\" content=\"Le masitinib est actuellement d\u00e9velopp\u00e9 en premi\u00e8re ligne pour le cancer de la prostate m\u00e9tastatique r\u00e9sistant \u00e0 la castration.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/cancer-de-la-prostate\/\" \/>\n<meta property=\"og:site_name\" content=\"AB Science\" \/>\n<meta property=\"article:modified_time\" content=\"2022-08-23T11:55:58+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/cancer-de-la-prostate\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/cancer-de-la-prostate\\\/\",\"name\":\"Cancer de la Prostate &#8211; AB Science\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-10-01T11:05:12+00:00\",\"dateModified\":\"2022-08-23T11:55:58+00:00\",\"description\":\"Le masitinib est actuellement d\u00e9velopp\u00e9 en premi\u00e8re ligne pour le cancer de la prostate m\u00e9tastatique r\u00e9sistant \u00e0 la castration.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/cancer-de-la-prostate\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/cancer-de-la-prostate\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/cancer-de-la-prostate\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pipeline\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Masitinib\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-overview\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Cancer de la Prostate\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"name\":\"AB Science\",\"description\":\"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\",\"name\":\"AB Science\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"contentUrl\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"width\":120,\"height\":120,\"caption\":\"AB Science\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ab-science\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cancer de la Prostate &#8211; AB Science","description":"Le masitinib est actuellement d\u00e9velopp\u00e9 en premi\u00e8re ligne pour le cancer de la prostate m\u00e9tastatique r\u00e9sistant \u00e0 la castration.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/cancer-de-la-prostate\/","og_locale":"fr_FR","og_type":"article","og_title":"Cancer de la Prostate","og_description":"Le masitinib est actuellement d\u00e9velopp\u00e9 en premi\u00e8re ligne pour le cancer de la prostate m\u00e9tastatique r\u00e9sistant \u00e0 la castration.","og_url":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/cancer-de-la-prostate\/","og_site_name":"AB Science","article_modified_time":"2022-08-23T11:55:58+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/cancer-de-la-prostate\/","url":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/cancer-de-la-prostate\/","name":"Cancer de la Prostate &#8211; AB Science","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/#website"},"datePublished":"2020-10-01T11:05:12+00:00","dateModified":"2022-08-23T11:55:58+00:00","description":"Le masitinib est actuellement d\u00e9velopp\u00e9 en premi\u00e8re ligne pour le cancer de la prostate m\u00e9tastatique r\u00e9sistant \u00e0 la castration.","breadcrumb":{"@id":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/cancer-de-la-prostate\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/cancer-de-la-prostate\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/cancer-de-la-prostate\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ab-science.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Pipeline","item":"https:\/\/www.ab-science.com\/fr\/pipeline\/"},{"@type":"ListItem","position":3,"name":"Masitinib","item":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-overview\/"},{"@type":"ListItem","position":4,"name":"Cancer de la Prostate"}]},{"@type":"WebSite","@id":"https:\/\/www.ab-science.com\/fr\/#website","url":"https:\/\/www.ab-science.com\/fr\/","name":"AB Science","description":"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action","publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ab-science.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ab-science.com\/fr\/#organization","name":"AB Science","url":"https:\/\/www.ab-science.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","contentUrl":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","width":120,"height":120,"caption":"AB Science"},"image":{"@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/ab-science\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages\/3683","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/comments?post=3683"}],"version-history":[{"count":0,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages\/3683\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages\/3763"}],"wp:attachment":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/media?parent=3683"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}